Immune Checkpoint Inhibitor Therapy
Immunotherapy utilizes monoclonal antibodies (Keytruda, Opdivo, Tecentriq) to block PD-1/PD-L1 and CTLA-4 immune checkpoints, unleashing the patient's own T-lymphocytes to recognize and destroy cancer cells.
Immunotherapy & checkpoint inhibitors
Clinical Overview & Disease Information
Immunotherapy utilizes monoclonal antibodies (Keytruda, Opdivo, Tecentriq) to block PD-1/PD-L1 and CTLA-4 immune checkpoints, unleashing the patient's own T-lymphocytes to recognize and destroy cancer cells.
Signs & Symptoms
- • Mild fatigue following IV infusion
- • Transient low-grade fever and chills
- • Immune-related skin rash or itching (pruritus)
- • Mild thyroid dysfunction (hypo/hyperthyroidism)
- • Diarrhea or colitis symptoms
- • Joint pain (arthralgia)
- • Severe immune-mediated pneumonitis (cough & acute dyspnea)
- • Severe immune colitis (> 6 watery stools/day)
- • Acute adrenal crisis
Causes & Risk Factors
Primary Causes & Etiology
- High Tumor Mutational Burden (TMB-High)
- Microsatellite Instability-High (MSI-H)
- Positive PD-L1 Tumor Proportion Score (TPS > 50%)
Who is at Higher Risk?
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Melanoma & Renal Cell Carcinoma
- Triple-Negative Breast Cancer
Diagnostic Evaluation & Testing
| Diagnostic Test | Clinical Purpose / What It Shows |
|---|---|
| PD-L1 Immunohistochemistry (IHC 22C3 / SP263) | Quantifies tumor cell PD-L1 expression score to predict immunotherapy response |
| Microsatellite Instability (MSI) & TMB Test | Identifies DNA mismatch repair deficiency (dMMR) for tissue-agnostic approval |
Comprehensive Treatment Options
PD-1 / PD-L1 Checkpoint Inhibitor Monotherapy Infusion
Intravenous infusion of Pembrolizumab (Keytruda) or Nivolumab (Opdivo) every 3 to 6 weeks.
Dual Immunotherapy (Nivolumab + Ipilimumab) or Chemo-Immunotherapy
Synergistic combination of CTLA-4 plus PD-1 inhibitors for advanced melanoma, renal cell, and lung cancers.
Advanced Medical Technologies Available in Partner Hospitals
Possible Complications If Untreated
Recovery Timeline, Diet & Lifestyle Care
Recovery Timeline
| Procedure / Stage | Expected Recovery Duration |
|---|---|
| IV Infusion Session | 30 to 60 minutes |
| Observation & Monitoring | 2 hours |
| Infusion Cycle Interval | Every 3 to 6 weeks |
| Response Assessment PET-CT | Every 9 to 12 weeks |
Recommended Post-Treatment Diet
- Balanced gut microbiome diet rich in fiber and fermented foods
- Hydration 2.5L/day
Essential Lifestyle Changes
- Track bowel movement frequency daily
- Report skin rashes or cough early to oncologist
- Light exercise
Prevention & Long-Term Health
Frequently Asked Questions
How long can a patient stay on immunotherapy?
Treatment typically continues for up to 2 years if the tumor remains controlled without unacceptable side effects.
Are side effects different from normal chemotherapy?
Yes. Immunotherapy side effects are immune-mediated (inflammation) rather than cytotoxic (hair loss/low counts).
Top Recommended Specialists Available
Dr. Gaurav Dixit
Head – Haematology Oncology & Bone Marrow Transplant (Unit II)
View Doctor Profile →
Dr. Aditya Gupta
Chairperson - Neurosurgery & CNS Radiosurgery & Co-Chief - Cyberknife Centre
View Doctor Profile →
Dr. Rupinder Sekhon
Chief - Gynae Oncology & Sr. Consultant: Surgical Oncology
View Doctor Profile →
Dr. Tapan Singh Chauhan
Sr. Consultant - Surgical Oncology, Robotics, GI & HPB, Gynae & Peritoneal Surface Oncology
View Doctor Profile →
Dr. Namita Jaggi
Chairperson - Lab Services & Infection Control; Chief - Education & Research
View Doctor Profile →
Dr. Parveen Yadav
Chief & Senior Consultant - Minimal Invasive & Robotic Thoracic Onco Surgery
View Doctor Profile →
Dr. Subodh Chandra Pande
Chief - Radiation Oncology & Co-Chief - Cyberknife Centre
View Doctor Profile →
Dr. Arun Singh Danewa
Senior Consultant – Pediatric-Haemato-Oncology & Bone Marrow Transplant (Unit II)
View Doctor Profile →Global Cost Comparison Matrix
| Procedure | USA (Avg) | India (ISG) | Turkey (Avg) | Thailand (Avg) |
|---|---|---|---|---|
| Immunotherapy & checkpoint inhibitors | $45,000 | $4,800 | $11,000 | $13,000 |
Request Free Clinical Opinion & Cost Estimate
Upload your diagnostic reports or medical summary for a free review by leading specialists within 24-48 hours.
Get Free Treatment EstimateCommonly Prescribed Medications
- Pembrolizumab 200mg IV every 3 weeks
- Nivolumab 240mg IV every 2 weeks
- Systemic Corticosteroids (for irAE management)
International Patient Guide
- Passport & Visa
- PD-L1 IHC Report & Biopsy Block
- Oncology Summary